Castle Biosciences Smashes Q2 Revenue, Lifts 2026 Guidance to $365–375M
CSTL sits 98% above its 52-week low of $14.59.
Summary
Castle Biosciences posted Q2 2026 revenue of $103.5 million, a 20% beat, and raised full-year guidance to $365–375 million. Core test volumes grew 32%, and the company expects positive Adjusted EBITDA for the rest of 2026.
Key Events · Earnings and Guidance · CSTL
-
Q2 Revenue Beat
Revenue of $103.5 million exceeded the $86.2 million consensus by 20%, driven by 32% growth in core test volumes (DecisionDx-Melanoma and TissueCypher).
-
Raised Full-Year Guidance
2026 revenue guidance raised to $365–375 million from $345–355 million, a $20 million midpoint increase. Management also expects positive Adjusted EBITDA for Q3, Q4, and the full year.
-
Path to Profitability
Adjusted EBITDA was $12.4 million in Q2, and the company now projects sustained profitability for the remainder of 2026, marking a key inflection point.
-
Strong Balance Sheet
Cash, equivalents, and marketable securities totaled $266.8 million as of June 30, 2026, providing ample runway to fund growth without near-term dilution risk.
Analysis · CSTL · Industrial Applications And Services
A standout quarter saw Castle Biosciences deliver revenue of $103.5 million, beating consensus by 20%, while core test volumes surged 32%. Management raised full-year guidance by $20 million at the midpoint and now expects positive Adjusted EBITDA for the remainder of 2026. The combination of accelerating growth, expanding margins, and a strong cash position of $266.8 million signals the business is hitting an inflection point — the raised guidance and profitability outlook directly challenge the bear case that this diagnostics company would burn cash indefinitely.
At the time of this filing, CSTL was trading at $28.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $812.5M. The 52-week trading range was $14.59 to $44.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.